New 1(2H)-phthalazinone derivatives as potent nonpeptidic HIV-1 protease inhibitors: molecular docking studies, molecular dynamics simulation, oral bioavailability and ADME prediction

References

• Sierra S, Kupfer B, Kaiser R. Basics of the virology of HIV-1 and its replication. J. Clin. Virol. 2005;34:233–244.10.1016/j.jcv.2005.09.004
   PubMed Web of Science ®Google Scholar
• Hong L, Treharne A, Hartsuck JA, Foundling S, Tang J. Crystal structures of complexes of a peptidic inhibitor with wild-type and two mutant HIV-1 proteases. Biochemistry. 1996;35:10627–10633.10.1021/bi960481s
   PubMed Web of Science ®Google Scholar
• Weber IT. Comparison of the crystal structures and intersubunit interactions of human immunodeficiency and Rous sarcoma virus proteases. J. Biol. Chem. 1990;265:10492–10496.
   PubMed Web of Science ®Google Scholar
• Brik A, Wong CH. HIV-1 protease: mechanism and drug discovery. Org. Biomol. Chem. 2003;1:5–14.10.1039/b208248a
   PubMed Web of Science ®Google Scholar
• Mastrolorenzo A, Rusconi S, Scozzafava A, Barbaro G, Supuran CT. Inhibitors of HIV-1 protease: current state of the art 10 years after their introduction. From antiretroviral drugs to antifungal, antibacterial and antitumor agents based on aspartic protease inhibitors. Curr. Med. Chem. 2007;14:2734–2748.10.2174/092986707782360141
   PubMed Web of Science ®Google Scholar
• Kaplan AH, Zack JA, Knigge M, et al. Partial inhibition of the human immunodeficiency type 1 protease results in aberrant assembly and the formation of noninfectious particles. J. Virol. 1993;67:4050–4055.
   PubMed Web of Science ®Google Scholar
• Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: december 2009. Top. HIV Med. 2009;17:138–145.
   PubMedGoogle Scholar
• Baldwin ET, Bhat TN, Liu B, Pattabriaman N, Erickson JW. Structural basis of drug resistance for the V82A mutant of HIV-1 proteinase. Nat. Struct. Biol. 1995;2:244–249.10.1038/nsb0395-244
   PubMedGoogle Scholar
• Ohtaka H, Schon A, Freire E. Multidrug resistance to HIV-1 protease inhibition requires cooperative coupling between distal mutations. Biochemistry. 2003;42:13659–13666.10.1021/bi0350405
   PubMed Web of Science ®Google Scholar
• Agniswamy J, Shen Ch-H, Aniana A, Sayer JM, Louis JM, Weber IT. HIV-1 protease with 20 mutations exhibits extreme resistance to clinical inhibitors through coordinated structural rearrangements. Biochemistry. 2012;51:2819–2828.10.1021/bi2018317
   PubMed Web of Science ®Google Scholar
• Ammaranonda P, Sanguansittianan S. Mechanism of HIV antiretroviral drugs progress toward drug resistance. Fundam. Clin. Pharmacol. 2012;26:146–161.10.1111/fcp.2011.26.issue-1
   PubMed Web of Science ®Google Scholar
• Louis JM, Zhang Y, Sayer JM, Wang Y-F, Harrison RW, Weber IT. The L76V drug resistance mutation decreases the dimer stability and rate of autoprocessing of HIV-1 protease by reducing internal hydrophobic contacts. Biochemistry. 2011;50:4786–4795.10.1021/bi200033z
   PubMed Web of Science ®Google Scholar
• Flausino OA Jr, Dufau L, Regasini LO, et al. Alkyl hydroxybenzoic acid derivatives that inhibit HIV-1 protease dimerization. Curr. Med. Chem. 2012;19:4534–4540.10.2174/092986712803251557
   PubMed Web of Science ®Google Scholar
• Camarasa M-J, Velázquez S, San-Félix A, Pérez-Pérez M-J, Gago F. Dimerization inhibitors of HIV-1 reverse transcriptase, protease and integrase: a single mode of inhibition for the three HIV enzymes? Antiviral Res. 2006;71:260–267.10.1016/j.antiviral.2006.05.021
   PubMed Web of Science ®Google Scholar
• Breccia P, Boggetto N, Pérez-Fernández R, et al. Dimerization Inhibitors of HIV-1 protease based on a bicyclic guanidinium subunit. J. Med. Chem. 2003;46:5196–5207.10.1021/jm030871u
   PubMed Web of Science ®Google Scholar
• Randolph JT, DeGoey DA. Peptidomimetic inhibitors of HIV protease. Curr. Top. Med. Chem. 2004;4:1079–1095.10.2174/1568026043388330
   PubMed Web of Science ®Google Scholar
• De Clercq E. The history of antiretrovirals: key discoveries over the past 25 years. Rev. Med. Virol. 2009;19:287–299.10.1002/rmv.v19:5
   PubMed Web of Science ®Google Scholar
• Qiu X, Liu Z-P. Recent developments of peptidomimetic HIV-1 protease inhibitors. Curr. Med. Chem. 2011;18:4513–4537.10.2174/092986711797287566
   PubMed Web of Science ®Google Scholar
• Luna B, Townsend MU. Tipranavir: the first nonpeptidic protease inhibitor for the treatment of protease resistance. Clin. Ther. 2007;29:2309–2318.10.1016/j.clinthera.2007.11.007
   PubMed Web of Science ®Google Scholar
• Poppe SM, Slade DE, Chong KT, et al. Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor. Antimicrob. Agents Chemother. 1997;41:1058–1063.
   PubMed Web of Science ®Google Scholar
• McCoy Ch. Darunavir: a nonpeptidic antiretroviral protease inhibitor. Clin. Ther. 2007;29:1559–1576.10.1016/j.clinthera.2007.08.016
   PubMed Web of Science ®Google Scholar
• Thaisrivongs S, Skulnick HI, Turner SR, et al. Structure-based design of HIV protease inhibitors: Sulfonamide-containing 5,6-dihydro-4-hydroxy-2-pyrones as non-peptidic inhibitor. J. Med. Chem. 1996;39:4349–4353.10.1021/jm960541s
   PubMed Web of Science ®Google Scholar
• Jadhav PK, Ala P, Woerner FJ, et al. Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV. J. Med. Chem. 1997;40:181–191.10.1021/jm960586t
   PubMed Web of Science ®Google Scholar
• Bosi S, Da Ros T, Spalluto G, Prato M. Fullerene derivatives: an attractive tool for biological applications. Eur. J. Med. Chem. 2003;38:913–923.10.1016/j.ejmech.2003.09.005
   PubMed Web of Science ®Google Scholar
• Friedman SH, DeCamp DL, Sijbesma RP, Srdanov G, Wudl F, Kenyon GL. Inhibition of the HIV-1 protease by fullerene derivatives: model building studies and experimental verification. J. Am. Chem. Soc. 1993;115:6506–6509.10.1021/ja00068a005
   Web of Science ®Google Scholar
• Sijbesma R, Srdanov G, Wudl F, et al. Synthesis of a fullerene derivative for the inhibition of HIV enzymes. J. Am. Chem. Soc. 1993;115:6510–6512.10.1021/ja00068a006
   Web of Science ®Google Scholar
• Cígler P, Kozísek M, Rezácová P, et al. From nonpeptide toward noncarbon protease inhibitors: metallacarboranes as specific and potent inhibitors of HIV protease. Proc. Natl. Acad. Sci. USA. 2005;102:15394–15399.10.1073/pnas.0507577102
   PubMed Web of Science ®Google Scholar
• Smoum R, Rubinstein A, Dembitsky VM, Srebnik M. Boron containing compounds as protease inhibitors. Chem. Rev. 2012;112:4156–4220.10.1021/cr608202m
   PubMed Web of Science ®Google Scholar
• Judd DA, Nettles JH, Nevins N, et al. Polyoxometalate HIV-1 protease inhibitors. A new mode of protease inhibition. J. Am. Chem. Soc. 2001;123:886–897.10.1021/ja001809e
   PubMed Web of Science ®Google Scholar
• Bernstein JA. Azelastine hydrochloride: a review of pharmacology, pharmacokinetics, clinical efficacy and tolerability. Curr. Med. Res. Opin. 2007;23:2441–2452.10.1185/030079907X226302
   PubMed Web of Science ®Google Scholar
• Slack RJ, Russell LJ, Hall DA, et al. Pharmacological characterization of GSK1004723, a novel, long-acting antagonist at histamine H1 and H3 receptors. Br. J. Pharmacol. 2011;164:1627–1641.10.1111/bph.2011.164.issue-6
   PubMed Web of Science ®Google Scholar
• Procopiou PA, Browning Ch, Buckley JM, et al. The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis. J. Med. Chem. 2011;54:2183–2195.10.1021/jm1013874
   PubMed Web of Science ®Google Scholar
• Biswas K, Peterkin TAN, Bryan MC, et al. Discovery of potent, orally bioavailable phthalazinone bradykinin B1 receptor antagonists. J. Med. Chem. 2011;54:7232–7246.10.1021/jm200808v
   PubMed Web of Science ®Google Scholar
• del Olmo E, Barboza B, Ybarra MI, et al. Vasorelaxant activity of phthalazinones and related compounds. Bioorg. Med. Chem. Lett. 2006;16:2786–2790.10.1016/j.bmcl.2006.02.003
   PubMed Web of Science ®Google Scholar
• Strappaghetti G, Brodi Ch, Giannaccini G, Betti L. New 4-(4-methyl-phenyl)phthalazin-1(2H)-one derivatives and their effects on α1-receptors. Bioorg. Med. Chem. Lett. 2006;16:2575–2579.10.1016/j.bmcl.2006.02.068
   PubMed Web of Science ®Google Scholar
• Lepor H. The emerging role of alpha antagonists in the therapy of benign prostatic hyperplasia. J. Androl. 1991;12:389–394.
   PubMed Web of Science ®Google Scholar
• Prime ME, Courtney SM, Brookfield FA, et al. Phthalazinone pyrazoles as potent, selective, and orally bioavailable inhibitors of Aurora-A Kinase. J. Med. Chem. 2011;54:312–319.10.1021/jm101346r
   PubMed Web of Science ®Google Scholar
• Menear KA, Adcock C, Boulter R, et al. 4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(adp-ribose) polymerase-1. J. Med. Chem. 2008;51:6581–6591.10.1021/jm8001263
   PubMed Web of Science ®Google Scholar
• Loh VM Jr, Cockcroft X-l, Dillon KJ, et al. Phthalazinones. Part 1: the design and synthesis of a novel series of potent inhibitors of poly(ADP-ribose)polymerase. Bioorg. Med. Chem. Lett. 2005;15:2235–2238.10.1016/j.bmcl.2005.03.026
   PubMed Web of Science ®Google Scholar
• X-L Cockcroft, Dillon KJ, Dixon L, et al. Phthalazinones 2: optimisation and synthesis of novel potent inhibitors of poly(ADP-ribose)polymerase. Bioorg. Med. Chem. Lett. 2006;16:1040–1044.
   PubMed Web of Science ®Google Scholar
• Menear KA, Adcock C, Alonso FC, et al. Novel alkoxybenzamide inhibitors of poly(ADP-ribose) polymerase. Bioorg. Med. Chem. Lett. 2008;18:3942–3945.10.1016/j.bmcl.2008.06.025
   PubMed Web of Science ®Google Scholar
• Bedoya LM, Del Olmo E, Sancho R, et al. Anti-HIV activity of stilbene-related heterocyclic compounds. Bioorg. Med. Chem. Lett. 2006;16:4075–4079.10.1016/j.bmcl.2006.04.087
   PubMed Web of Science ®Google Scholar
• Li Y-X, Luo Y-P, Xi Z, Niu Z, He Y-Z, Yang G-F. Design and syntheses of novel phthalazin-1(2H)-one derivatives as acetohydroxyacid synthase inhibitors. J. Agric. Food. Chem. 2006;54:9135–9139.10.1021/jf061976j
   PubMed Web of Science ®Google Scholar
• Epsztajn J, Malinowski Z, Urbaniak P, Andrijewski G. A Practical approach for preparation of 2-[(dialkylamino)-methyl]-4-aryl-2H-phthalazin-1-ones via Mannich reaction of 4-aryl-2H-phthalazin-l-ones. Synth. Commun. 2005;35:179–192.10.1081/SCC-200048404
   Web of Science ®Google Scholar
• Pakulska W, Malinowski Z, Szczesniak AK, Czarnecka E, Epsztajn J. Synthesis and pharmacological evaluation of N-(dimethylamino)ethyl derivatives of benzo- and pyridopyridazinones. Arch. Pharm. Chem. Life Sci. 2009;342:41–47.10.1002/ardp.v342:1
   PubMed Web of Science ®Google Scholar
• Cortopassi WA, Cavalieri Feital RJ, de Jesus Medeiros D, Cuya Guizado TR, Costa França TC, Pimentel AS. Docking and molecular dynamics studies of new potential inhibitors of the human epidermal receptor 2. Mol. Simulat. 2012;38:1132–1142.10.1080/08927022.2012.696113
   Web of Science ®Google Scholar
• De Lucca GV. Synthesis and evaluation of delta lactams as nonpeptide HIV-protease inhibitors. Bioorg. Med. Chem. Lett. 1997;7:501–504.10.1016/S0960-894X(97)00007-3
   Web of Science ®Google Scholar
• Smith AB III, Cantin L-D, Pasternak A, et al. Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors. J. Med. Chem. 2003;46:1831–1844.10.1021/jm0204587
   PubMed Web of Science ®Google Scholar
• SYBYL-X 1.2, Tripos International, 1699 South Hanley Rd., St. Louis, Missouri, 63144, USA; 2010.
   Google Scholar
• Clark M, Cramer RD III, Van Opdenbosch N. Validation of the general purpose tripos 5.2 force field. J. Comp. Chem. 1989;10:982–1012.10.1002/(ISSN)1096-987X
   Web of Science ®Google Scholar
• Gasteiger J, Marsili M. Iterative partial equalization of orbital electronegativity–a rapid access to atomic charges. Tetrahedron. 1980;36:3219–3228.10.1016/0040-4020(80)80168-2
   Web of Science ®Google Scholar
• Hall HK Jr. Correlation of the base strengths of amines. J. Am. Chem. Soc. 1957;79:5441–5444.10.1021/ja01577a030
   Web of Science ®Google Scholar
• Lide DR, editor. CRC Handbook of Chemistry and Physics. 75th ed. Boca Raton: CRC Press Inc; 1994. p. 8–47.
   Google Scholar
• Albert A, Barlin GB. 605. Ionization constants of heterocyclic substances. Part V. Mercapto-derivatives of diazines and benzodiazines. J. Chem. Soc. 1962;3129–3141. doi: 10.1039/jr9620003129
   Web of Science ®Google Scholar
• Reddy GS, Ali A, Nalam MN, et al. Design and synthesis of HIV-1 protease inhibitors incorporating oxazolidinones as P2/P2′ ligands in pseudosymmetric dipeptide isosteres. J. Med. Chem. 2007;50:4316–4328.10.1021/jm070284z
   PubMed Web of Science ®Google Scholar
• Czodrowski P, Sotriffer ChA, Klebe G. Atypical protonation states in the active site of HIV-1 protease: a computational study. J. Chem. Inf. Model. 2007;47:1590–1598.10.1021/ci600522c
   PubMed Web of Science ®Google Scholar
• Harte WE, Beveridge DL. Prediction of the protonation states of the active site aspartyl residues in HIV-1 protease-inhibitor complexes via molecular dynamics simulation. J. Am. Chem. Soc. 1993;115:3883–3886.10.1021/ja00063a005
   Web of Science ®Google Scholar
• Ruppert J, Welch W, Jain AN. Automatic identification and representation of protein binding sites for molecular docking. Protein Sci. 1997;6:524–533.
   PubMed Web of Science ®Google Scholar
• Jain AN. Surflex: fully automatic flexible molecular docking using a molecular similarity-based search engine. J. Med. Chem. 2003;46:499–511.10.1021/jm020406h
   PubMed Web of Science ®Google Scholar
• Jain AN. Scoring noncovalent protein-ligand interactions: a continuous differentiable function tuned to compute binding affinities. J. Comput. Aided-Mol. Des. 1996;10:427–440.10.1007/BF00124474
   PubMed Web of Science ®Google Scholar
• Discovery Studio. San Diego:Release 3.0. Accelrys Software Inc.; 2010.
   Google Scholar
• Torshin IY, Weber IT, Harrison RW. Geometric criteria of hydrogen bonds in proteins and identification of `bifurcated’ hydrogen bonds. Protein Eng. 2002;15:359–363.10.1093/protein/15.5.359
   PubMedGoogle Scholar
• Stierand K, Rarey M. Drawing the PDB: protein−ligand complexes in two dimensions. ACS Med. Chem. Lett. 2010;1:540–545.10.1021/ml100164p
   PubMed Web of Science ®Google Scholar
• McGaughey GB, Gagnes M, Rappe AK. π-stacking interactions. Alive and well in proteins. J. Biol. Chem. 1998;273:15458–15463.10.1074/jbc.273.25.15458
   PubMed Web of Science ®Google Scholar
• Xu D, Tsai Ch-J, Nussinov R. Hydrogen bonds and salt bridges across protein–protein interfaces. Protein Eng. 1997;10:999–1012.10.1093/protein/10.9.999
   PubMedGoogle Scholar
• Jakalian A, Bush BL, Jack DB, Bayly CI. Fast, efficient generation of high-quality atomic charges. AM1-BCC model: I. Method. J. Comput. Chem. 2000;21:132–146.10.1002/(SICI)1096-987X(20000130)21:2<>1.0.CO;2-6
   Web of Science ®Google Scholar
• Jakalian A, David BJ, Bayly CI. Fast, efficient generation of high-quality atomic charges. AM1-BCC model: II. Parameterization and validation. J. Comput. Chem. 2002;23:1623–1641.10.1002/jcc.10128
   PubMed Web of Science ®Google Scholar
• Wang J, Wang W, Kollmann PA, Case DA. Automatic atom type and bond type perception in molecular mechanical calculations. J. Mol. Graphics Modell. 2006;25:247–260.10.1016/j.jmgm.2005.12.005
   Google Scholar
• Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML. Comparison of simple potential functions for simulating liquid water. J. Chem. Phys. 1983;79:926–935.10.1063/1.445869
   Web of Science ®Google Scholar
• Hornak V, Abel R, Okur A, Strockbine B, Roitberg A, Simmerling C. Comparison of multiple Amber force fields and development of improved protein backbone parameters. Proteins. 2006;65:712–725.10.1002/prot.v65:3
   PubMed Web of Science ®Google Scholar
• Wang J, Wolf RM, Caldwell JW, Kollman PA, Case DA. Development and testing of a general amber force field. J. Comput. Chem. 2004;25:1157–1174.10.1002/(ISSN)1096-987X
   PubMed Web of Science ®Google Scholar
• Case DA, Darden TA, Cheatham TE III, et al. AMBER 11. San Francisco, USA: University of California; 2010.
   Google Scholar
• Toukmaji A, Sagui C, Board J, Darden T. Efficient particle-mesh Ewald based approach to fixed and induced dipolar interactions. J. Chem. Phys. 2000;113:10913–10927.10.1063/1.1324708
   Web of Science ®Google Scholar
• Sagui C, Pedersen LG, Darden TA. Towards an accurate representation of electrostatics in classical force fields: efficient implementation of multipolar interactions in biomolecular simulations. J. Chem. Phys. 2004;120:73–87.10.1063/1.1630791
   PubMed Web of Science ®Google Scholar
• Ryckaert J-P, Ciccotti G, Berendsen HJC. Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. J. Comput. Phys. 1977;23:327–341.10.1016/0021-9991(77)90098-5
   Web of Science ®Google Scholar
• Miyamoto S, Kollman PA. Settle: an analytical version of the SHAKE and RATTLE algorithm for rigid water models. J. Comput. Chem. 1992;13:952–962.10.1002/(ISSN)1096-987X
   Web of Science ®Google Scholar
• Roe DR, Cheatham TE III. PTRAJ and CPPTRAJ: software for processing and analysis of molecular dynamics trajectory data. J. Chem. Theory Comput. 2013;9:3084–3095.10.1021/ct400341p
   PubMed Web of Science ®Google Scholar
• Pettersen EF, Goddard TD, Huang CC, et al. UCSF chimera? a visualization system for exploratory research and analysis. J. Comput. Chem. 2004;25:1605–1612.10.1002/(ISSN)1096-987X
   PubMed Web of Science ®Google Scholar
• Kollman PA, Massova I, Reyes C, et al. Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc. Chem. Res. 2000;33:889–897.10.1021/ar000033j
   PubMed Web of Science ®Google Scholar
• Hou T, Wang J, Li Y, Wang W. Assessing the performance of the MM/PBSA and MM/GBSA methods. 1. The accuracy of binding free energy calculations based on molecular dynamics simulations. J. Chem. Inf. Model. 2011;51:69–82.10.1021/ci100275a
   PubMed Web of Science ®Google Scholar
• Sitkoff D, Sharp KA, Honig B. Accurate calculation of hydration free energies using macroscopic solvent models. J. Phys. Chem. 1994;98:1978–1988.10.1021/j100058a043
   Web of Science ®Google Scholar
• Miller BR III, McGee TD Jr, Swails JM, Homeyer N, Gohlke H, Roitberg AE. MMPBSA.py: an efficient program for end-state free energy calculations. J. Chem. Theory Comput. 2012;8:3314–3321.10.1021/ct300418h
   PubMed Web of Science ®Google Scholar
• Lipinski ChA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 2001;46:3–26.10.1016/S0169-409X(00)00129-0
   PubMed Web of Science ®Google Scholar
• Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 2002;45:2615–2623.10.1021/jm020017n
   PubMed Web of Science ®Google Scholar
• Wildman SA, Crippen GM. Prediction of physicochemical parameters by atomic contributions. J. Chem. Inf. Comput. Sci. 1999;39:868–873.10.1021/ci990307l
   Google Scholar
• Ertl P, Rohde B, Selzer P. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J. Med. Chem. 2000;43:3714–3717.10.1021/jm000942e
   PubMed Web of Science ®Google Scholar
• Merz KM, Baldwin JJ. Prediction of drug absorption using multivariate statistics. J. Med. Chem. 2000;43:3867–3877.
   PubMed Web of Science ®Google Scholar
• Cheng A, Merz K Jr. Prediction of aqueous solubility of a diverse set of compounds using quantitative structure−property relationships. J. Med. Chem. 2003;46:3572–3580.10.1021/jm020266b
   PubMed Web of Science ®Google Scholar
• Egan WJ, Lauri G. Prediction of intestinal permeability. Adv. Drug Del. Rev. 2002;54:273–289.10.1016/S0169-409X(02)00004-2
   PubMed Web of Science ®Google Scholar
• Steiner T. The hydrogen bond in the solid state. Angew. Chem. Int. Ed. 2002;41:48–76.10.1002/1521-3773(20020104)41:1<>1.0.CO;2-5
   Web of Science ®Google Scholar
• Ward MD. Charge-assisted hydrogen-bonded networks. Struct. Bond. 2009;132:1–23.
   Web of Science ®Google Scholar
• Specker E, Bottcher J, Brass S, et al. Unexpected novel binding mode of pyrrolidine-based aspartyl protease inhibitors: design, synthesis and crystal structure in complex with HIV protease. Chem. Med. Chem. 2006;1:106–117.10.1002/(ISSN)1860-7187
   Google Scholar
• Huang M, Grant GH, Richards WG. Binding modes of diketo-acid inhibitors of HIV-1 integrase: a comparative molecular dynamics simulation study. J. Mol. Graphics Modell. 2011;29:956–964.10.1016/j.jmgm.2011.04.002
   Google Scholar
• Hornak V, Okur A, Rizzo RC, Simmerlin C. HIV-1 protease flaps spontaneously open and recluse in molecular dynamics simulations. Proc. Natl. Acad. Sci. USA. 2006;103:915–920.10.1073/pnas.0508452103
   PubMed Web of Science ®Google Scholar
• Ishima R, Freedberg DI, Wang YX, Louis JM, Torchia DA. Flap opening and dimer-interface flexibility in the free and inhibitor-bound HIV protease. Structure. 1999;7:1047–1055.10.1016/S0969-2126(99)80172-5
   PubMed Web of Science ®Google Scholar
• Weber J, Mesters JR, Lepsík M, et al. Unusual binding mode of an HIV-1 protease inhibitor explains its potency against multi-drug-resistant virus strains. J. Mol. Biol. 2002;324:739–754.10.1016/S0022-2836(02)01139-7
   PubMed Web of Science ®Google Scholar
• Eberle J, Bechowsky B, Rose D, et al. Resistance of HIV type 1 to proteinase inhibitor Ro 31-8959. AIDS Res. Hum. Retroviruses. 1995;11:671–676.10.1089/aid.1995.11.671
   PubMed Web of Science ®Google Scholar
• Vaillancourt M, Irlbeck D, Smith T, Coombs RW, Swanstrom R. The HIV type 1 protease inhibitor saquinavir can select for multiple mutations that confer increasing resistance. AIDS Res. Hum. Retroviruses. 1999;15:355–363.10.1089/088922299311321
   PubMed Web of Science ®Google Scholar
• Mager PP. The active site of HIV-1 protease. Med. Res. Rev. 2001;21:348–353.10.1002/(ISSN)1098-1128
   PubMed Web of Science ®Google Scholar
• Gohlke H, Klebe G. Approaches to the description and prediction of the binding affinity of small-molecule ligands to macromolecular receptors. Angew. Chem. Int. Ed. 2002;41:2644–2676.10.1002/1521-3773(20020802)41:15<2644::AID-ANIE2644>3.0.CO;2-O
   PubMed Web of Science ®Google Scholar
• Mertz EL, Krishtalik LI. Low dielectric response in enzyme active site. Proc. Natl. Acad. Sci. USA. 2000;97:2081–2086.10.1073/pnas.050316997
   PubMed Web of Science ®Google Scholar
• Muller N. Search for a realistic view of hydrophobic effects. Acc. Chem. Res. 1990;23:23–28.10.1021/ar00169a005
   Web of Science ®Google Scholar
• Williams DH, Stephens E, O’Brien DP, Zhou M. Understanding noncovalent interactions: ligand binding energy and catalytic efficiency from ligand-induced reductions in motion within receptors and enzymes. Angew. Chem. Int. Ed. 2004;43:6596–6616.10.1002/(ISSN)1521-3773
   PubMed Web of Science ®Google Scholar
• Rezac J, Riley KE, Hobza P. S66: a well-balanced database of benchmark interaction energies relevant to biomolecular structures. J. Chem. Theory Comput. 2011;7:2427–2438.10.1021/ct2002946
   PubMed Web of Science ®Google Scholar
• Sayyed FB, Suresh ChH. Accurate prediction of cation−π interaction energy using substituent effects. J. Phys. Chem. A. 2012;116:5723–5732.10.1021/jp3034193
   PubMed Web of Science ®Google Scholar
• Tóth G, Borics A. Closing of the flaps of HIV-1 protease induced by substrate binding: a model of a flap closing mechanism in retroviral aspartic proteases. Biochemistry. 2006;45:6606–6614.10.1021/bi060188k
   PubMed Web of Science ®Google Scholar
• Blum A, Böttcher J, Heine A, Klebe G, Diederich WE. Structure-guided design of C2-symmetric HIV-1 protease inhibitors based on a pyrrolidine scaffold. J. Med. Chem. 2008;51:2078–2087.10.1021/jm701142s
   PubMed Web of Science ®Google Scholar
• Wright DW, Hall BA, Kenway OA, Jha S, Coveney PV. Computing clinically relevant binding free energies of HIV-1 protease inhibitors. J. Chem. Theory Comput. 2014;10:1228–1241.10.1021/ct4007037
   PubMed Web of Science ®Google Scholar
• Roe DR, Okur A, Wickstrom L, Hornak V, Simmerling C. Secondary structure bias in generalized born solvent models: comparison of conformational ensembles and free energy of solvent polarization from explicit and implicite solvation. J. Phys. Chem. B. 2007;111:1846–1857.10.1021/jp066831u
   PubMed Web of Science ®Google Scholar
• Okur A, Wickstrom L, Simmerling C. Evaluation of salt bridge structure and energetics in peptides using explicit, implicit, and hybrid solvation models. J. Chem. Theory Comput. 2008;4:488–498.10.1021/ct7002308
   PubMed Web of Science ®Google Scholar
• Amaro RE, Cheng XL, Ivanov I, Xu D, McCammon JA. Characterizing loop dynamics and ligand recognition in human- and avian-type influenza neuraminidases via generalized born molecular dynamics and end-point free energy calculations. J. Am. Chem. Soc. 2009;131:4702–4709.10.1021/ja8085643
   PubMed Web of Science ®Google Scholar
• Wu TD, Schiffer CA, Gonzales MJ, et al. Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments. J. Virol. 2003;77:4836–4847.
   PubMed Web of Science ®Google Scholar
• Fasinu P, Pillay V, Ndesendo VMK, du Toit LC, Choonara YE. Diverse approaches for the enhancement of oral drug bioavailability. Biopharm. Drug Dispos. 2011;32:185–209.10.1002/bdd.v32.4
   PubMed Web of Science ®Google Scholar